البلد: إسرائيل
اللغة: الإنجليزية
المصدر: Ministry of Health
NITISINONE
MEGAPHARM LTD
A16AX04
HARD CAPSULE
NITISINONE 2 MG
PER OS
Required
APOTEK PRODUKTION & LABORATORIER AB, SWEDEN
NITISINONE
NITISINONE
Treatment of patients with confirmed diagnosis of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine05/06/2018 בקשה לשינוי משטר מינון Once Daily
2016-12-31
PATIENT PACKAGE INSERT IN ACCORDANCE WITH THE PHARMACISTS’ REGULATIONS - 1986 This medicine is dispensed with a physician’s prescription only ORFADIN ™ 2 MG HARD CAPSULES ORFADIN ™ 5 MG HARD CAPSULES ORFADIN ™ 10 MG HARD CAPSULES COMPOSITION: ACTIVE INGREDIENT: EACH CAPSULE OF ORFADIN 2 MG HARD CAPSULES CONTAINS NITISINONE 2 MG EACH CAPSULE OF ORFADIN 5 MG HARD CAPSULES CONTAINS NITISINONE 5 MG EACH CAPSULE OF ORFADIN 10 MG HARD CAPSULES CONTAINS NITISINONE 10 MG For the list of inactive ingredients and allergens in the medicine, see section 6, “Additional information”. READ THIS LEAFLET CAREFULLY IN ITS ENTIRETY BEFORE USING THE MEDICINE. This leaflet contains concise information about the medicine. If you have further questions, consult your physician or pharmacist. This medicine has been prescribed to treat your illness. Do not pass it on to others. It may harm them even if it seems to you that their illness is similar. 1. WHAT IS THIS MEDICINE INTENDED FOR? Treatment of patients with confirmed diagnosis of hereditary tyrosinemia type 1 )HT-1( in combination with dietary restriction of tyrosine and phenylalanine. In this disease your body is unable to completely break down the amino acid tyrosine )amino acids are the building blocks that build the proteins in our body(, and as a result, a harmful substance accumulates in the body. ORFADIN HARD CAPSULES prevent the breakdown of the amino acid tyrosine from the outset, and as a result, the harmful substance does not accumulate in your body. Since tyrosine remains in the body, a special dietary regime based on foods with low quantities of tyrosine and phenylalanine should be maintained during treatment with ORFADIN HARD CAPSULES. THERAPEUTIC GROUP: Treatment of defects in an essential metabolic system. 2. BEFORE USING THE MEDICINE: DO NOT USE THIS MEDICINE IF: • You are sensitive )allergic( to the active ingredient nitisinone or to any of the additional ingredients that the medicine contains )please see section 6, “Additional information”(. اقرأ الوثيقة كاملة
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Orfadin 2 mg, 5mg, 10mg Hard capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 2 mg, 5mg, 10mg Nitisinone. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Hard capsule. White, opaque capsules imprinted “NTBC 2mg”/ “NTBC 5mg”/ “NTBC 10mg” in black on the body of the capsule. The capsules contain a white to off white powder. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of patients with confirmed diagnosis of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Orfadin hard capsules treatment should be initiated and supervised by a physician experienced in the treatment of HT-1 patients. Posology Treatment of all genotypes of the disease should be initiated as early as possible to increase overall survival and avoid complications such as liver failure, liver cancer and renal disease. Adjunct to the Orfadin hard capsules treatment, a diet deficient in phenylalanine and tyrosine is required and should be followed by monitoring of plasma amino acids (see sections 4.4 and 4.8). The recommended initial dose in the paediatric and adult population is 1 mg/kg body weight_ _ administered orally. The dose of Orfadin hard capsules should be adjusted individually. It is recommended to administer the dose once daily. However, due to the limited data in patients with body weight <20 kg, it is recommended to divide the total daily dose into two daily administrations in this patient population. _Dose adjustment_ During regular monitoring, it is appropriate to follow urine succinylacetone, liver function test values and alpha-fetoprotein levels (see section 4.4). If urine succinylacetone is still detectable one month after the start of Orfadin hard capsules treatment, the Orfadin hard capsules dose should be increased to 1.5 mg/kg body weight/day divided in 2 doses. A dose of 2 mg/kg body weight اقرأ الوثيقة كاملة